Preference for Gamma-Hydroxybutyrate (GHB) in Current Users

Autor/inn/en	Roll, John M.; Newton, Thomas; Chudzynski, Joy; Cameron, Jennifer M.; McPherson, Sterling; Fong, Tim; Torrington, Matt
Titel	Preference for Gamma-Hydroxybutyrate (GHB) in Current Users
Quelle	In: Journal of the Experimental Analysis of Behavior, 97 (2012) 3, S.323-331 (9 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0022-5002
Schlagwörter	Narcotics; Drug Abuse; Preferences; Adults; Reinforcement; California + Suchen Sie Ihr Suchwort? Narcotic; Betäubungsmittel; Positive Verstärkung; Kalifornien
Abstract	Gamma-hydroxybutyrate (GHB) is a drug with significant abuse potential. The present study aimed to assess the relative value of escalating doses of GHB to current GHB users via the Multiple Choice Procedure (MCP), and to validate that the dose rated highest with the MCP would be self-administered at a greater rate than placebo. Participants were 5 current GHB users who were not currently trying to stop using GHB. To examine the value of escalating doses of GHB, the following doses of GHB were used: 0 (placebo), 12.5, 25, 37.5, and 50 mg/kg. Participants typically assigned higher doses of GHB had higher crossover points on the MCP. During choice sessions, participants made repeated choices between administering GHB, placebo or nothing. All participants selected GHB exclusively (5 out of 5 instances) except for one participant who selected GHB on 4 out of 5 instances, thus 96% (i.e., 24/25) of choices were for active GHB. Based on these data, GHB appears likely to function as a dose-dependent reinforcer for humans based on our sample. (Contains 2 figures.) (As Provided).
Anmerkungen	Society for the Experimental Analysis of Behavior. Available from: Indiana University Department of Psychology. Bloomington, IN 47405-1301. Tel: 812-334-0395; FAX: 812-855-4691; e-mail: jeab@indiana.edu; Web site: http://seab.envmed.rochester.edu/jeab/index.html
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10